AMG 714

AMG 714 is a human monoclonal antibody that binds to Interleukin-15 (IL-15), a cytokine molecule appearing early in the cascade of events that ultimately leads to inflammatory disease. AMG 714 was created by Genmab, as HuMax-IL15, under a collaboration with Amgen. Amgen has sub-licensed AMG 714 to a private company, Celimmune, LLC. Celimmune is developing AMG 714 for nonresponsive and refractory celiac disease.

Back to top

Celiac disease is an autoimmune disorder where consuming gluten leads to an immune response that damages the small intestine1.  AMG 714 is being investigated in both non-responsive celiac disease and refractory celiac disease Type II.

Non-responsive celiac disease (NCD) affects 10-19% of patients with celiac disease and occurs when damage to the intestinal lining does not recover after a year of maintaining a gluten-free diet. In addition, it is possible that other disorders (such as lactose intolerance and irritable bowel syndrome) could be affecting treatment2,3

Refractory celiac disease (RCD), also called refractory sprue, is rare, affecting approximately 1 in 50 people with celiac disease and is defined as symptoms and damage that persist or recur after six to 12 months on a gluten free diet and all other potential disorders that could affect treatment have been excluded. Patients with RCD are divided into types based on analysis of small bowel biopsies. While patients with RCD Type I generally respond well to diet change and therapies such as steroids, patients with RCD Type II have more severe symptoms and respond poorly to steroids. They may also have complications that progress to a T-cell lymphoma of the small intestine and have a mortality rate similar to patients with cancer3.

1 Celiac Disease Foundation,
2 Celiac Disease Foundation,

3 Mayo Clinic,

Back to top